MX364689B - Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. - Google Patents

Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.

Info

Publication number
MX364689B
MX364689B MX2015013235A MX2015013235A MX364689B MX 364689 B MX364689 B MX 364689B MX 2015013235 A MX2015013235 A MX 2015013235A MX 2015013235 A MX2015013235 A MX 2015013235A MX 364689 B MX364689 B MX 364689B
Authority
MX
Mexico
Prior art keywords
peptide
immunogen constructs
alzheimer
peptide immunogen
immunotherapy
Prior art date
Application number
MX2015013235A
Other languages
English (en)
Other versions
MX2015013235A (es
Inventor
Yi Wang Chang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of MX2015013235A publication Critical patent/MX2015013235A/es
Publication of MX364689B publication Critical patent/MX364689B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a constructos de inmunógeno de péptido Aß individuales, composiciones de péptidos que comprenden estos constructos inmunógeno de péptido Aß y mezclas de los mismos, composiciones farmacéuticas que incluyen formulaciones de vacuna que comprenden los constructos de inmunógeno de péptido se Aß, con los constructos de inmunógeno de péptido Aß individuo que tiene el N-terminal de el péptido Aß como la célula B (B) epítopos unido a través de residuo (s) espaciador para células T helper heteróloga (Th) epítopos derivados de oteins pr patógenos que actúan conjuntamente para estimular la generación de anticuerpos altamente específicos dirigido contra el N-terminal de el péptido AB ofreciendo respuestas inmunes protectoras a los pacientes en riesgo de, o con, la enfermedad de Alzheimer.
MX2015013235A 2013-03-15 2013-04-23 Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. MX364689B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Publications (2)

Publication Number Publication Date
MX2015013235A MX2015013235A (es) 2016-04-04
MX364689B true MX364689B (es) 2019-05-06

Family

ID=51527985

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013235A MX364689B (es) 2013-03-15 2013-04-23 Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
MX2019005268A MX2019005268A (es) 2013-03-15 2015-09-15 Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019005268A MX2019005268A (es) 2013-03-15 2015-09-15 Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.

Country Status (19)

Country Link
US (4) US9102752B2 (es)
EP (1) EP2968485B1 (es)
JP (3) JP6208319B2 (es)
KR (2) KR20180132962A (es)
CN (2) CN108794615A (es)
AU (3) AU2013381835A1 (es)
BR (1) BR112015023105A8 (es)
CA (1) CA2906313A1 (es)
DK (1) DK2968485T3 (es)
ES (1) ES2800028T3 (es)
HK (1) HK1212600A1 (es)
IL (2) IL241597B (es)
MX (2) MX364689B (es)
PT (1) PT2968485T (es)
RU (1) RU2696566C2 (es)
SG (1) SG11201507669YA (es)
TW (1) TWI561529B (es)
WO (1) WO2014143087A1 (es)
ZA (2) ZA201507526B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP3129040A4 (en) * 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
EP3409130B1 (en) 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
JP7161401B2 (ja) * 2016-04-14 2022-10-26 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
KR20200054938A (ko) * 2017-06-16 2020-05-20 유나이티드 뉴로사이언스 알파-시뉴클린 단백질의 c-말단부로부터의 펩티드 면역원 및 시뉴클레인병증 치료를 위한 그의 제형화
CA3079236A1 (en) * 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
WO2019118512A2 (en) * 2017-12-11 2019-06-20 Ubi Ip Holdings Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
WO2019133024A1 (en) * 2017-12-31 2019-07-04 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases
US20200400688A1 (en) * 2018-02-13 2020-12-24 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
EP3790581A4 (en) * 2018-05-04 2022-06-22 UBI IP Holdings ARTIFICIAL PROMISCUOUS T-HELPER CELL EPITOPS THAT ENABLE TARGETED ANTIBODY PRODUCTION WITH LIMITED T-CELL INFLAMMATORY RESPONSE
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
BR112021011938A2 (pt) * 2018-12-19 2021-11-09 United Biomedical Inc Epítopos de célula t helper promíscuos artificiais como imunoestimuladores para imunógenos peptídicos sintéticos
SG11202107042WA (en) * 2018-12-28 2021-07-29 United Biomedical Inc Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation
BR112021012906A2 (pt) * 2018-12-31 2021-12-28 United Neuroscience Ltd Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
EP4093756A1 (en) * 2020-01-23 2022-11-30 United Biomedical Inc. Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine
MX2022011199A (es) 2020-03-10 2022-12-07 Lifearc Peptidos ciclicos.
CA3195783A1 (en) 2020-11-17 2022-05-27 Keith Rubin Treatment and prevention of neuropathology associated with neurodegenerative diseases
EP4307988A1 (en) * 2021-03-16 2024-01-24 NeuroVision Imaging, Inc. Biofluid-based methods for diagnosing alzheimer's disease-associated conditions
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
DE60031792T2 (de) 1999-12-08 2007-02-22 Intellect Neurosciences, Inc. Schimärische amyloid-beta peptide
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
CN101421299A (zh) * 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗
JP5161796B2 (ja) * 2006-02-24 2013-03-13 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗アミロイド免疫原性組成物、方法、および使用
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2342356A4 (en) * 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012056008A1 (en) * 2010-10-28 2012-05-03 Jonas Nilsson Diagnosis and treatment of alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
RU2015142996A (ru) 2017-04-24
CN108794615A (zh) 2018-11-13
EP2968485A4 (en) 2016-09-07
WO2014143087A1 (en) 2014-09-18
EP2968485A1 (en) 2016-01-20
HK1212600A1 (zh) 2016-06-17
SG11201507669YA (en) 2015-10-29
CN105228644B (zh) 2018-07-13
TW201434478A (zh) 2014-09-16
ZA201906683B (en) 2023-04-26
BR112015023105A8 (pt) 2018-01-23
CN105228644A (zh) 2016-01-06
AU2017203425B2 (en) 2019-07-11
RU2019123453A (ru) 2019-09-10
MX2019005268A (es) 2019-07-01
ZA201507526B (en) 2019-12-18
IL265910A (en) 2019-06-30
JP6208319B2 (ja) 2017-10-04
BR112015023105A2 (pt) 2017-11-21
CA2906313A1 (en) 2014-09-18
MX2015013235A (es) 2016-04-04
JP2017226646A (ja) 2017-12-28
JP6784646B2 (ja) 2020-11-11
US20190194280A1 (en) 2019-06-27
EP2968485B1 (en) 2020-03-04
RU2696566C2 (ru) 2019-08-05
JP2019196397A (ja) 2019-11-14
AU2013381835A1 (en) 2015-10-08
PT2968485T (pt) 2020-06-26
US20140271690A1 (en) 2014-09-18
DK2968485T3 (da) 2020-06-08
KR20180132962A (ko) 2018-12-12
ES2800028T3 (es) 2020-12-23
JP2016513638A (ja) 2016-05-16
AU2017203425A1 (en) 2017-06-08
AU2019246916A1 (en) 2019-10-31
US9102752B2 (en) 2015-08-11
KR20150132396A (ko) 2015-11-25
TWI561529B (en) 2016-12-11
KR101926030B1 (ko) 2018-12-10
IL241597B (en) 2020-07-30
US20160068581A1 (en) 2016-03-10
US20180244739A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2019005268A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
PH12017500727A1 (en) Modified virus-like particles of cmv
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2022002106A (es) Formulaciones de vacuna de vial unico.
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201590427A1 (ru) Нелинейные сахаридные конъюгаты
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
FI20115374A0 (fi) Uudet hypoallergeenit
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
IN2014DN09445A (es)
MX2019007924A (es) Vacunas contra la influenza.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
IN2015DN03925A (es)
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
WO2013171661A3 (en) Adjuvant formulations and methods
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2014152271A8 (en) Viral proteins as immunomodulatory agents and vaccine components

Legal Events

Date Code Title Description
FG Grant or registration